December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.5251 +0.0222 (+4.41%)
Delayed Quote Updated: 12:22 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Humacyte Earnings Preview ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2023 ↗
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Recap: Humacyte Q1 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Humacyte ↗
 
Via Benzinga
News headline image
Earnings Preview For Humacyte ↗
 
Via Benzinga
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 24, 2023 ↗
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth... 
Via Benzinga
News headline image
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte to Present at Upcoming Investor Conferences in March
From Humacyte, Inc
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
Humacyte's Return on Invested Capital Insights ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
Thursday, December 15, 2022 @ 8:00 AM ET 
From Humacyte, Inc
Via GlobeNewswire
News headline image
Sidoti's December Small-Cap Virtual Conference
Via ACCESSWIRE
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference 
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
News headline image
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 34 companies set new 52-week lows. 
Via Benzinga
News headline image
Humacyte Third Quarter 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
From Humacyte, Inc
Via GlobeNewswire
News headline image
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
From Humacyte, Inc
Via GlobeNewswire
News headline image
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Humacyte Earnings Perspective: Return On Invested Capital ↗
According to Benzinga Pro, during Q2, Humacyte (NASDAQ:HUMA) earned $36.87 million, a 285.9% increase from the preceding quarter. Humacyte also posted a total of $1.30 million in sales, a 458.37%... 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2022 ↗
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
News headline image
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.